Page 1
DEFINITION
Page 2
Page 3
Page 4
INCIDENS
Page 5
Pathophysiology
• IgG interact with the postsynaptic AChR at
the nicotinic neuromuscular junction(NMJ).
• This reduces the number of functional
receptors by blocking Ach attachment, by
increasing the degradation of receptors and
by complement induced damage to the NMJ
• MG pts have a reduced AChR density and have
30% the normal number of AChR
Page 6
• The reduced AChR density leads to
decreased amplitude in the post
synaptic region leading to failure in
initiation in muscle fibre contraction.
• When it occurs at many NMJs
manifests as weakness of voluntary
muscle feature
Page 7
Classification
1. Ocular myastenia : influence eye muscle
ptosis, diplopia
2. Mild generalized myastenia : spread out to
muscle skelet and bulbar
3. Moderate generalized myastenia :
inresponsive to drugs
4. Severe generalized myastenia :
- Acute fulmating myastenia : acute onset of
respiratory muscle weakness until 6 months
- Late severe myastenia : > 2 years
5. Myastenia crisis : recurent
Page 8
Manifestations
Page 9
Dx test
• EMG
– Recording of compound muscle action
potentials(CMAP)
– Following repetitive stimulation of motor
nerve
– In MG this leads to reduction in CMAP
(>10%)
• Detection of anti-AChR antibodies
– In 80-85% cases
Page 10
Management
Page 11
• Immunosuppression - corticosteroids
mainstay
– effective in 70%
– best results when used high dose and
reduced
– average of 4months with some indefinitely
– Azothiprine and methotrexate effective
adjuncts, 80% helped, few remission
Page 12
ICU
• Frequent estimations of VC and inspiratory
force
• Consideration of mechanical ventilation given
to those with severe bulbar and respiratory
muscle involvement
• Deterioration of ABGs often late sign
• Good ICU care, maintaining K, Ca Mg levels
normal. Physio and NG feeding.
• If adjustment of medications not sufficient
to see improvement need to consider high
dose steroid and plasma exchange therapy.
Page 13
Nursing Dx
Page 14